<?xml version="1.0" encoding="UTF-8"?>
<drug type="biotech" created="2008-03-19" updated="2019-12-02">
  <drugbank-id primary="true">DB06498</drugbank-id>
  <name>L523S</name>
  <description>According to Nemunaitis J., et al, "L523S is an immunogenic lung cancer antigen that has demonstrated preclinical safety when the gene is injected intramuscularly as an expressive plasmid (pVAX/L523S) and when delivered following incorporation into an E1B-deleted adenovirus (Ad/L523S)." [A175909] It has been investigated as a lung cancer vaccine.</description>
  <cas-number/>
  <unii/>
  <state>solid</state>
  <groups>
    <group>investigational</group>
  </groups>
  <general-references>
    <articles>
      <article>
        <ref-id>A6862</ref-id>
        <pubmed-id>12644826</pubmed-id>
        <citation>Wang T, Fan L, Watanabe Y, McNeill PD, Moulton GG, Bangur C, Fanger GR, Okada M, Inoue Y, Persing DH, Reed SG: L523S, an RNA-binding protein as a potential therapeutic target for lung cancer. Br J Cancer. 2003 Mar 24;88(6):887-94.</citation>
      </article>
      <article>
        <ref-id>A175909</ref-id>
        <pubmed-id>16581300</pubmed-id>
        <citation>Nemunaitis J, Meyers T, Senzer N, Cunningham C, West H, Vallieres E, Anthony S, Vukelja S, Berman B, Tully H, Pappen B, Sarmiento S, Arzaga R, Duniho S, Engardt S, Meagher M, Cheever MA: Phase I Trial of sequential administration of recombinant DNA and adenovirus expressing L523S protein in early stage non-small-cell lung cancer. Mol Ther. 2006 Jun;13(6):1185-91. doi: 10.1016/j.ymthe.2006.01.013. Epub 2006 Apr 11.</citation>
      </article>
    </articles>
    <textbooks/>
    <links/>
    <attachments/>
  </general-references>
  <synthesis-reference/>
  <indication>Investigated for use/treatment in lung cancer.</indication>
  <pharmacodynamics/>
  <mechanism-of-action/>
  <toxicity/>
  <metabolism/>
  <absorption/>
  <half-life/>
  <protein-binding/>
  <route-of-elimination/>
  <volume-of-distribution/>
  <clearance/>
  <salts/>
  <synonyms/>
  <products/>
  <international-brands/>
  <mixtures/>
  <packagers/>
  <manufacturers/>
  <prices/>
  <categories/>
  <affected-organisms/>
  <dosages/>
  <atc-codes/>
  <ahfs-codes/>
  <pdb-entries/>
  <patents/>
  <food-interactions/>
  <drug-interactions/>
  <sequences/>
  <experimental-properties/>
  <external-identifiers/>
  <external-links/>
  <pathways/>
  <reactions/>
  <snp-effects/>
  <snp-adverse-drug-reactions/>
  <targets/>
  <enzymes/>
  <carriers/>
  <transporters/>
</drug>